Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1977 Jul;29(1):11–15.

Antibody-dependent cellular cytotoxicity (ADCC) against Epstein-Barr virus-determined antigens. III. Reactivity in sera from patients with Burkitt's lymphoma in relation to tumour development.

M Jondal, P Gunven
PMCID: PMC1541044  PMID: 70292

Abstract

Sera from patients with Burkitt's lymphoma (BL) were tested for antibody-dependent cellular cytotoxicity (ADCC) against Epstein-Barr virus (EBV) determined antigens and for antibodies directed against various EBV-specific antigens. No correlation was found between EBV serology and ADCC in sera selected for high or low titres against the membrane antigens (MA) or in consecutive sera from three patients with isolated late tumour recurrences. Furthermore, no correlation was found between ADCC and tumour development.

Full text

PDF
15

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Gunvén P., Klein G. Blocking of direct membrane immunofluorescence in titration of membrane-reactive antibodies associated with Epstein-Barr virus. J Natl Cancer Inst. 1971 Sep;47(3):539–548. [PubMed] [Google Scholar]
  2. Gunvén P., Klein G., Henle G., Henle W., Clifford P. Epstein-Barr virus in Burkitt's lymphoma and nasopharyngeal carcinoma. Antibodies to EBV associated membrane and viral capsid antigens in Burkitt lymphoma patients. Nature. 1970 Dec 12;228(5276):1053–1056. doi: 10.1038/2281053a0. [DOI] [PubMed] [Google Scholar]
  3. Gunvén P., Klein G., Henle W., Henle G., Rocchi G., Hewetson J. F., Guerra A., Clifford P., Singh S., Demissie A. Immunological studies on a case of recurrent Burkitt's lymphoma during immune stimulant treatment. Int J Cancer. 1973 Jul 15;12(1):115–123. doi: 10.1002/ijc.2910120112. [DOI] [PubMed] [Google Scholar]
  4. Henle G., Henle W., Clifford P., Diehl V., Kafuko G. W., Kirya B. G., Klein G., Morrow R. H., Munube G. M., Pike P. Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst. 1969 Nov;43(5):1147–1157. [PubMed] [Google Scholar]
  5. Henle G., Henle W. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol. 1966 Mar;91(3):1248–1256. doi: 10.1128/jb.91.3.1248-1256.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Henle G., Henle W., Klein G. Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells. Int J Cancer. 1971 Sep 15;8(2):272–282. doi: 10.1002/ijc.2910080212. [DOI] [PubMed] [Google Scholar]
  7. Henle G., Henle W., Klein G., Gunven P., Clifford P., Morrow R. H., Ziegler J. L. Antibodies to early Epstein-Barr virus-induced antigens in Burkitt's lymphoma. J Natl Cancer Inst. 1971 Apr;46(4):861–871. [PubMed] [Google Scholar]
  8. Jondal M. Antibody-dependent cellular cytotoxicity (ADCC) against Epstein-Barr virus-determined antigens II. Induction of ADCC by FC-FC receptor bridging. Clin Exp Immunol. 1977 Jul;29(1):1–10. [PMC free article] [PubMed] [Google Scholar]
  9. Jondal M. Antibody-dependent cellular cytotoxicity (ADCC) against Epstein-Barr virus-determined membrane antigens. I. Reactivity in sera from normal persons and from patients with acute infectious mononucleosis. Clin Exp Immunol. 1976 Jul;25(1):1–5. [PMC free article] [PubMed] [Google Scholar]
  10. Jondal M., Pross H. Surface markers on human b and t lymphocytes. VI. Cytotoxicity against cell lines as a functional marker for lymphocyte subpopulations. Int J Cancer. 1975 Apr 15;15(4):596–605. doi: 10.1002/ijc.2910150409. [DOI] [PubMed] [Google Scholar]
  11. Jondal M. Surface markers on human B and T lymphocytes. IV. Distribution of surface markers on resting and blast-transformed lymphocytes. Scand J Immunol. 1974;3(6):739–747. doi: 10.1111/j.1365-3083.1974.tb01309.x. [DOI] [PubMed] [Google Scholar]
  12. Jondal M., Svedmyr E., Klein E., Singh S. Killer T cells in a Burkitt's lymphoma biopsy. Nature. 1975 May 29;255(5507):405–407. doi: 10.1038/255405a0. [DOI] [PubMed] [Google Scholar]
  13. Klein G., Pearson G., Nadkarni J. S., Nadkarni J. J., Klein E., Henle G., Henle W., Clifford P. Relation between Epstein-Barr viral and cell membrane immunofluorescence of Burkitt tumor cells. I. Dependence of cell membrane immunofluorescence on presence of EB virus. J Exp Med. 1968 Nov 1;128(5):1011–1020. doi: 10.1084/jem.128.5.1011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Klein G. Studies on the Epstein-Barr Virus genome and the EBV-determined nuclear antigen in human malignant disease. Cold Spring Harb Symp Quant Biol. 1975;39(Pt 2):783–790. doi: 10.1101/sqb.1974.039.01.090. [DOI] [PubMed] [Google Scholar]
  15. Klein G. The Epstein-Barr virus and neoplasia. N Engl J Med. 1975 Dec 25;293(26):1353–1357. doi: 10.1056/NEJM197512252932607. [DOI] [PubMed] [Google Scholar]
  16. Miller G., Shope T., Lisco H., Stitt D., Lipman M. Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proc Natl Acad Sci U S A. 1972 Feb;69(2):383–387. doi: 10.1073/pnas.69.2.383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Pearson G. R., Orr T. W. Antibody-dependent lymphocyte cytotoxicity against cells expressing Epstein-Barr virus antigens. J Natl Cancer Inst. 1976 Mar;56(3):485–488. doi: 10.1093/jnci/56.3.485. [DOI] [PubMed] [Google Scholar]
  18. Svedmyr E., Jondal M. Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci U S A. 1975 Apr;72(4):1622–1626. doi: 10.1073/pnas.72.4.1622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. de Schryver A., Rosén A., Gunvén P., Klein G. Comparison between two antibody populations in the EBV system: anti-MA versus neutralizing antibody activity. Int J Cancer. 1976 Jan 15;17(1):8–13. doi: 10.1002/ijc.2910170103. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES